FBI Faces Tool v4.0 | Win App | 307 MB

Create any face you like Surprise yor friends and family with a drawing picture of themself The FACES award winning program makes a composite look virtually like a photo and it produces a good quality image. That?s why thousands of police agencies worldwide including the CIA, FBI and the US Military use FACES.

FACES 4.0 Features:

* Creates photo-like composites
* Generates unique alphanumeric code for every composite
* Extensive database of facial features
* Runs on any standard desk or laptop computer
* Expanded Latin, Asian and African-American features
* Three-tone hair color
* Side to side hair flip
* Facial markings: scars, moles, piercing, tattoos
* Improved age progression
* Detachable hats and headwear
* Full Windows XP compatibility
* Ability to export composite as JPEG file
* Integration with TRAK alert system
* Slide show capability
* ?Not A Real Photograph? Indicator
* Improved zooming and positioning tools

Minimal Requirements:

Intel Pentium or AMD processor
400 MHZ or better
Windows 98/ME/2000/XP
64 MB RAM or better
1.2 GB free disk space
Color Monitor (SVGA) with graphic card supporting at least 16-bit colors at 800×600 resolution
CD-ROM drive, 2x or better

FBI Face Tool 4.0

Sorry that I cannot include download link, because the software was posted on rapidshare illegally.

He met her on a party. She was so outstanding, many guys chasing after her, while he was so normal, nobody paid attention to him. At the end of the party, he invited her to have coffee with him, she was surprised, but due to being polite, she promised. They sat in a nice coffee shop, he was too nervous to say anything, she felt uncomfortable, she thought, please; let me go home…suddenly he asked the waiter:

“Would you please give me some salt? I’d like to put it in my coffee.”

Everybody stared at him, so strange! His face turned red, but, still, he put the salt in his coffee and drank it.

She asked him curiously: why you have this hobby?

He replied: “when I was a little boy, I was living near the sea, I liked playing in the sea, I could feel the taste of the sea, just like the taste of the salty coffee. Now every time I have the salty coffee, I always think of my childhood, think of my hometown, I miss my hometown so much, I miss my parents who are still living there”.

While saying that tears filled his eyes. She was deeply touched.

That’s his true feeling, from the bottom of his heart. A man who can tell out his homesickness, he must be a man who loves home, cares about home, has responsibility of home…Then she also started to speak, spoke about her faraway hometown, her childhood, her family. That was a really nice talk, also a beautiful beginning of their story. They continued to date. She found that actually he was a man who meets all her demands; he had tolerance, was kind hearted, warm, careful. He was such a good person but she almost missed him!

Thanks to his salty coffee! Then the story was just like every beautiful love story, the princess married to the prince, and then they were living the happy life…

And, every time she made coffee for him, she put some salt in the coffee, as she knew that’s the way he liked it.

After 40 years, he passed away, left her a letter which said: “My dearest, please forgive me, forgive my whole life lie. This was the only lie I said to you the salty coffee.

Remember the first time we dated? I was so nervous at that time, actually I wanted some sugar, but I said salt. It was hard for me to change so I just went ahead. I never thought that could be the start of our communication! I tried to tell you the truth many times in my life, but I was too afraid to do that, as I have promised not to lie you for anything…

Now I’m dying, I afraid of nothing so I tell you the truth: I don’t like the salty coffee, what a strange bad taste…But I have had the salty coffee for my whole life! Since I knew you, I never feel sorry for anything I do for you. Having you with me is my biggest happiness for my whole life, even though I have to drink the salty coffee again”

Her tears made the latter totally wet.

Someday, someone asked her: what’s the taste of salty coffee? It’s sweet. She replied.

Love is not to forget but to forgive

Not to see but to understand

Not to hear but to listen

Not to let go but hold on!!!!

I’m sure that sometimes you have problem to download because these file hosting service websites restrict number of  downloaded files by IP address. To solve this problem you can try premium link generator service provides by other website to download unlimited number of file. Here are some websites provide premium link generator services:

• http://www.rsplg.com
• http://www.premium-link-generator.com
• http://rs.techwoo.com/index.php?sv=2
• http://www.hlusoe.info
• http://sv1.gopro4vn.com
• http://www.speedfile.ru
• http://rapidshare.gopro4vn.com/index.php

If a website is down or not working, please comment it.

An office worker, Nong Fah, 21 years old, 32-24-35, 167cm, 50Kg charged 1,500 a fling. Miss Ladda Tangsuphachai from the Mistry of Culture said that they had found more than 1,000 girls selling sex on the Internet, and the average price were between 1,500-3000 baht depending on lenghth of time and servicing.

Read orginal post at Thai Blog

Similar night tourism efforts have been introduced at other sites in Southeast Asia.

Cambodia already has installed some lights at the network of centuries-old temples, said Bun Narith, who leads the agency responsible for managing the Angkor park.

Tourism is a major foreign currency earner for cash-strapped Cambodia. More than a million foreign tourists are expected to visit this year, with most from South Korea, Japan and the United States. More than half of tourists visit the Angkor temples, by far the country’s biggest draw.

Visitors are now ushered out of Angkor at sunset, but authorities are considering extending visiting hours to as late as 8:30 p.m. local time.

“We want tourists to see all views of the temple, even in the dark places where they may have not have seen some of the sculptures and statues,” Bun Narith said.

But conservationists have long expressed concerns about tourism’s impact on Angkor. They say the uncontrolled pumping of underground water to meet the rising demand of hotels and residents in the nearby town of Siem Reap may be destabilizing the earth beneath the temples.

“The ministry of Health would like to advise that as of May 22 2009, no cases of Influenza A/H1N1 virus have been confirmed in the country,” the statement said.

Cambodian Health Ministry received an urgent letter Wednesday from South Korean Embassy warning that three Cambodian- Americans were on the same flight from the United States to South Korea with a passenger who was later confirmed to have Influenza A/H1N1. The three individuals subsequently flew on a separate flight to Phnom Penh on Sunday.

At the time of their arrival to Cambodia, the three passengers did not display influenza symptoms, according to the statement. The ministry officials are now seeking to locate these passengers to assess their well-being and to offer them testing.

“The Ministry of Health is working closely with all relevant authorities to continue to monitor the situation closely,” it added.

The ministry also strongly advised people who has traveled from an affected area in the past seven days and has developed fever …to contact with the ministry.

Source from english.sina.com

The head of VaxGen, Donald Francis, said the vaccine worked on chimpanzees and he was optimistic about the results of trials on humans, due to be published next year.

VaxGen’s vaccine will be part of the biggest-ever HIV vaccine trial due to begin later this year in Thailand with the involvement of 16,000 people.

Reports of scientific progress were accompanied by warnings that rich nations needed to spend more to help bring the epidemic under control.

Malaysian activist Irene Fernandez told the conference that North American and European countries were not meeting their targets for foreign aid set by the Organisation for Economic Co-operation and Development (OECD).

If they did, she said, there would be enough money to fund Aids-prevention programmes.

The six-day conference is organised by the United Nations agency UNAids and is being attended by 15,000 delegates.

Licence conditions

In the Thai trial, VaxGen’s product will be tested in combination with another vaccine, designed to produce a different type of immune response. Scientists hope this will result in a higher level of protection than either vaccine would induce on its own.

But VaxGen is optimistic that its product will also work as a sole vaccine.

“I think we will get protection [from the virus], but I don’t know what level we’ll get,” Mr Francis said.

“If all goes well, [the vaccine] could be available by the end of 2004 or early 2005.”

Campaigners have given a cautious welcome to VaxGen’s announcement, but say it is necessary to wait for the analysis of clinical trials.

BBC health correspondent Chris Hogg says that 21 years after the fight against Aids began, only eight vaccines are currently being tested on humans to any significant degree.

Most of these are still in the early stages. VaxGen is the only company testing its products on humans in an end-stage trial.

To be granted a licence, however, it will have to show the vaccine is effective in at least one-third of patients.
Immunisation hopes

Jose Esparza, co-ordinator of the UNAids HIV vaccine initiative in Geneva, said VaxGen’s announcement was “premature”, although he praised the company’s commitment to developing a vaccine.

“If the vaccine is effective then we will have a cause for celebration, but even then it will not be the end of the epidemic,” he said.

The umbrella body promoting research, the International Aids Vaccine Initiative (IAVI), warned that preparations needed to begin now for the distribution of a successful vaccine to the countries most in need.

Most importantly, it eould have to be made affordable.

IAVI president Dr Seth Berkley told the BBC that vaccination would initially be targeted at high-risk groups such as intravenous drug users and commercial sex workers.

But he said it was hoped one day that a vaccine would be available for everyone.

“We would hope to use it as part of immunisation for every child so we can put an end to this terrible disease.”

Blocking out HIV

The conference also heard about a drug which tests have shown cuts the levels of HIV in patients by stopping it entering blood cells.

The injectable T-20 drug, made by Roche Holding AG of Switzerland and US biotech firm Trimeris Inc is due to go on to the market early next year.

It is said to offer hope to patients with serious drug resistance problems.

Existing treatments attack HIV only after it has entered cells.

A study presented to the conference showed three quarters of gay and bisexual men in US cities who were infected with HIV did not know they had the virus.

Source from BBC News

Microsoft will begin releasing new versions of Office-related products this year. Exchange 2010 will be the first product in this lineup, entering beta for customers to download today. Exchange 2010 will become available in the second half of 2009. Office 2010 – including Office Web applications, SharePoint Server 2010, Visio 2010 and Project 2010 – will enter a technical preview in the third quarter of 2009 and will release to manufacturing in the first half of 2010.

More at Microsoft website

How important will influenza A(H1N1) vaccines be for reducing pandemic disease?
Vaccines are one of the most valuable ways to protect people during influenza epidemics and pandemics. Other measures include anti-viral drugs, social distancing and personal hygiene.

Will currently available seasonal vaccine confer protection against influenza A(H1N1)?
The best scientific evidence available today is incomplete but suggests that seasonal vaccines will confer little or no protection against influenza A(H1N1).

What is WHO doing to facilitate production of influenza A(H1N1) vaccines?
As soon as the first human cases of new influenza A(H1N1) infection became known to WHO, the WHO Collaborating Center in Atlanta (The Centers for Disease Control and Prevention (CDC) in the United States of America) took immediate action and began the work to develop candidate vaccine viruses. WHO also initiated consultations with vaccine manufacturers worldwide to facilitate the availability of all necessary material to start production of influenza A(H1N1) vaccine. In parallel, WHO is working with national regulatory authorities to ensure that the new influenza A(H1N1) vaccine will meet all safety criteria and be made available as soon as possible.

Why is WHO not asking vaccine manufacturers to switch production from seasonal vaccine to a influenza A(H1N1) vaccine yet?
WHO has not recommended stopping production of seasonal influenza vaccine because this seasonal influenza causes 3 million to 5 million cases of severe illness each year, and kills from 250 000 to 500 000 people. Continued immunization against seasonal influenza is therefore important. Moreover, stopping seasonal vaccine production immediately would not allow a pandemic vaccine to be made quicker. At this time, WHO is liaising closely with vaccine manufacturers so large-scale vaccine production can start as soon as indicated.

Is it possible that manufacturers produce both seasonal and pandemic vaccines at the same time?
There are several potential options which must be considered based on all available evidence.

What is the process for developing a pandemic vaccine? Has a vaccine strain been identified, and if so by whom?
A vaccine for the Influenza A(H1N1) virus will be produced using licensed influenza vaccine processes in which the vaccine viruses are grown either in eggs or cells. Candidate vaccine strains have been identified and prepared by the WHO Collaborating Center in Atlanta (The Centers for Disease Control and Prevention (CDC) in the United States of America)1. These strains have now been received by the other WHO Collaborating Centers which have also started preparation of vaccine candidate viruses. Once developed, these strains will be distributed to all interested manufacturers on request. Availability is anticipated by mid-May.

How quickly will influenza A(H1N1) vaccines be available?
The first doses of Influenza A(H1N1) vaccine could be available in five to six months from identification of the pandemic strain. The regulatory approval will be conducted in parallel with the manufacturing process. Regulatory authorities have put into place expedited processes that do not compromise on the quality and safety of the vaccine. Delays in production could result from poor growth of the virus strain used to make the vaccine.

How would manufacturers be selected?
There are currently more than a dozen vaccine manufacturers with licenses to produce influenza vaccines. Upon request, the vaccine strain will be available to each of them, as well as to other qualified vaccine manufacturers who are preparing to make influenza vaccine but do not yet have a licensed influenza vaccine.

What is the global manufacturing capacity for a potential influenza A(H1N1) pandemic vaccine? Is this the same as the global manufacturing capacity for H5N1?
The projections made for the production capacity of an vaccine for H5N1 cannot be automatically assumed to be the capacity to make an H1N1 vaccine. H5N1 and H1N1 viruses are different and the amount of antigen needed to make an effective H1N1 vaccines may be different than for H5N1. Therefore it is not possible to make a precise estimate. However, given these considerations, a conservative estimate of global capacity is at least 1 to 2 billion doses per year.

How is production capacity for influenza vaccines distributed geographically?
More that 90% of the global capacity today is located in Europe and in North America. However, during the past five years, other regions have begun to acquire the technology to produce influenza vaccines. Six manufacturers in developing countries have done so with technical and financial support from WHO.

What will be the storage requirements for influenza A(H1N1) vaccine?
The vaccine should be stored under refrigerated conditions at between 2°C and 8°C.

It has been impossible so far to develop vaccines for major killers such as HIV and malaria. How sure are we that there will not be scientific or other hurdles in developing an effective influenza A(H1N1) vaccine?
Typically, development of influenza vaccines has not posed a problem. Influenza vaccines have been used in humans for many years and are known to be immunogenic and effective. Each year seasonal influenza vaccines with varying composition are produced for the northern and southern hemisphere influenza seasons. Vaccine manufacturers will employ a number of different technologies to develop their vaccines. They will take advantage, notably, of novel approaches that were developed over the past years for H5N1 avian influenza vaccines. One key unknown is yield of vaccine virus production, since some strains grow better than others and the behavior of the new influenza A(H1N1) strain in manufacturers’ systems is not yet known. New recombinant technologies are under development, but have not yet been approved for use.

Will influenza A(H1N1) vaccines be effective in all population groups?
There are not data on this but there also is no reason to expect that they would not, given current information.

Will the influenza A(H1N1) vaccine be safe?
Licensed vaccines are held to a very high standard of safety. All possible precautions will be taken to ensure safety of new influenza A(H1N1) vaccines.

How can a repeat of the 1976 swine flu vaccine complications (Guillain-Barré syndrome) experienced in the United States of America be avoided?
Guillain-Barré syndrome is an acute disorder of the nervous system. It is observed following a variety of infections, including influenza. Studies suggest that regular seasonal influenza vaccines could be associated with an increased risk of Guillain-Barré syndrome on the order of one to two cases per million vaccinated persons. During the 1976 influenza vaccination campaign, this risk increased to around 10 cases per million vaccinated persons which led to the withdrawal of the vaccine.

Pandemic vaccines will be manufactured according to established standards. However, they are new products so there is an inherent risk that they will cause slightly differently reactions in humans. Close monitoring and investigation of all serious adverse events following administration of vaccine is essential. The systems for monitoring safety are an integral part of the strategies for the implementation of the new pandemic influenza vaccines. Quality control for the production of influenza vaccines has improved substantially since the 1970s.

Will it be possible to deliver new influenza A(H1N1) vaccine simultaneously with other vaccines?
Inactivated influenza vaccine can be given at the same time as other injectable vaccines, but the vaccines should be administered at different injection sites.

If the virus causes a mild pandemic in the warmer months and changes into something much more severe in, say, 6 months, will vaccines being developed now be effective?
It is too early to be able to predict changes in the influenza A(H1N1) virus as it continues to circulate in humans or how similar a mutated virus might be to the current virus. Careful surveillance for changes in the influenza A(H1N1) virus is ongoing. This close and constant monitoring will support a quick response should important changes in the virus be detected.

Will there be enough influenza A(H1N1) vaccine for everyone?
The estimated time to make enough vaccine to vaccinate the world’s population against pandemic influenza will not be known until vaccine manufacturers will have been able to determine how much active ingredient (antigen) is needed to make one dose of effective influenza A(H1N1) vaccine.

In the past two years, influenza vaccine production capacity has increased sharply due to expansion of production facilities as well as advances in research, including the discovery and use of adjuvants. Adjuvants are substances added to a vaccine to make it more effective, thus conserving the active ingredient (antigen).

What is WHO’s perspective on fairness and equity for vaccine availability?
The WHO Director-General has called for international solidarity in the response to the current situation. WHO regards the goal of ensuring fair and equitable access by all countries to response measures to be among the highest priorities. WHO is working very closely with partners including the vaccine manufacturing industry on this.

Who is likely to receive priority for vaccination with a future pandemic vaccine?
This decision is made by national authorities. As guidance, WHO will be tracking the evolution of the pandemic in real-time and making its findings public. As information becomes available, it may be possible to better define high-risk groups and to target vaccination for those groups, thus ensuring that limited supplies are used to greatest effect.

Will WHO be conducting mass influenza A(H1N1) vaccination campaigns?
No. National authorities will implement vaccination campaigns according to their national pandemic preparedness plans. WHO is exploring whether the vaccine can be packaged, for example, in multi-dose vials, to facilitate the rapid and efficient vaccination of large numbers of people.

Developing countries are very experienced in administering population-wide vaccination campaigns during public health emergencies caused by infectious diseases, including diseases like epidemic meningitis and yellow fever, as well as for polio eradication and measles control programmes.

How feasible will it be to immunize large numbers of people in developing countries against a pandemic virus?
Developing countries have considerable strategic and practical experience in delivering vaccines in mass campaigns. The main issue is not feasibility, but how to ensure timely access to adequate quantities of vaccine.

What is the estimated global number of doses of seasonal vaccine used annually?
The current annual demand is for less than 500 million doses per year.

Will seasonal influenza vaccine continue to be available?
At this time there is no recommendation to stop production of seasonal influenza vaccine.

All this information is based on World Health Organization.